Navigation Links
St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
Date:8/29/2007

Results of a study by investigators at St. Jude Childrens Research Hospital provide strong evidence for why the targeted therapy drug, imatinib, or Gleevec, which has revolutionized the treatment of chronic myelogenous leukemia, (CML) is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL). Targeted therapy drugs are designed to block the activity of a specific molecule, a strategy aimed at making treatments more effective and less toxic.

The findings may shed new light on why a small percentage of children with ALL do not benefit from treatment, while more than 90 percent of children treated with the latest therapies survive. The discovery could also help researchers better understand both the origins of this form of aggressive ALL as well as why it becomes resistant to imatinib; and this knowledge may lead to more effective treatments for patients who are not helped by current therapies.

CML and an aggressive form of ALL share the same critical mutationthe Philadelphia chromosome (Ph). Cells that have this mutation (Ph+ cells) produce a rogue growth-promoting enzyme called BCR-ABL. Now, work by a team headed by Charles J. Sherr, M.D., Ph.D., a Howard Hughes Medical Institute investigator and co-chair of the St. Jude Department of Genetics and Tumor Cell Biology, has shown that these two forms of leukemia part company in a crucial respect.

Many Ph+ ALL cells lack a tumor-suppressor gene called Arf, which is normally present in CML cells at the time the disease is first diagnosed, said Sherr. Stripped of the anti-tumor effects of Arf and nurtured by growth factors produced in the bone marrow, these ALL cells become less responsive to imatinib and more difficult to eliminate. Sherr reasons that the cells survival advantage increases their opportunity to develop mutations in the BCR-ABL protein, which prompt imatinib resistance.

A report on these results appears in the September 15 issue of Genes & Development.

The findings of the study not only suggest why Ph+ ALL is often insensitive to imatinib, but also imply that doctors might identify patients at high risk of failing this treatment by determining whether their leukemic cells lack the Arf gene, said Richard T. Williams, M.D., Ph.D., an assistant member in the St. Jude Department of Oncology and the papers first author. The development of drugs that also block the ability of other factors in the bone marrow to sustain the leukemic cells should render them more susceptible to imatinib and improve the outcome of ALL patients who are resistant to current forms of therapy. Discovery of the Philadelphia chromosome in the 1960s represented the first identification of a chromosome abnormality found in a specific kind of cancer. Ph+ ALL occurs in about 30 percent of all adult, but in only 4 percent of childhood cases. Its presence signals that patients of any age will likely have poor outcomes.

This study strongly suggests that a widely held explanation for how leukemias arise is not universally applicable. This view holds that leukemias arise from rare cancer stem cells, which do not make up the bulk of the tumor, but are the only cells required to regenerate the cancer after treatment, Williams said. However the new St. Jude study reveals that the combination of BCR-ABL activity and inactivation of Arf are sufficient to generate a uniform population of leukemia-initiating cellsany one of which can expand and induce rapidly fatal disease. Rather than comprising only a rare minority of cancer stem cells, each of these ALL cells is able to trigger and propagate the disease, so an effective therapy has to prevent the multiplication of each and every one of them.


'/>"/>
Contact: Summer Freeman
summer.freeman@stjude.org
901-495-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related biology news :

1. Current human embryonic stem cell lines contaminated UCSD/Salk team finds
2. Another Look Finds Promising Proteomics Test is Not Biologically Plausible
3. Study finds more than one-third of human genome regulated by RNA
4. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
5. Same mutation aided evolution in many fish species, Stanford study finds
6. NC State scientist finds soft tissue in T. rex bones
7. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
8. Genrate: a generative model that finds and scores new genes and exons in genomic microarray data
9. Genetically modified rice in China benefits farmers health, study finds
10. Survey finds silver contamination in North Pacific waters
11. Anti cancer virotherapy well tolerated in first human administration, research finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... OH (PRWEB) , ... August 16, 2017 , ... ... a beneficial microbe delivery system, announced it has secured $2M in funding from ... Queen City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar ...
(Date:8/16/2017)... and OXFORD, England , Aug. 16, 2017 ... for biotech executive search and leadership development, and Virdis Group, ... have created an exclusive alliance that enables clients to leverage ... "For our clients here in the ... access to a diverse population of leadership talent throughout the ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics , ... development, announces the launch of the new NHS Agile biosensor chip . ... data for a wide range of molecules, including small and large molecules, peptides, ...
(Date:8/15/2017)... ... 2017 , ... Kenall, a leader in sealed solid-state lighting, ... sealed and perform efficiently for years. The downlights are ideal for a variety ... such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and pharmaceutical processing ...
Breaking Biology Technology: